Product specification: Etoposide 250ml & 500ml & 1000ml infusion

	Name of product	Etoposide infusion. Aseptically prepared from licensed sterile starting materials.
	Concentration	Concentration range 0.19 mg/ml to 0.36mg/ml in infusion bags in accordance with the national dose banding tables. The Etoposide concentrate should be added to the bag without withdrawal of equivalent volume of Sodium Chloride 0.9% w/v Infusion unless withdrawal of some infusion fluid is required to accomodate the total dose.
	Diluent	Sodium Chloride 0.9% w/v
	Volume	48mg to 88mg in 250ml (252ml to 254ml including addition volume) 96mg to 180mg in 500ml (505ml to 509ml including addition volume) 200mg to 360mg in 1000ml (1010ml to 1018ml including addition volume)
	Final container	Non-PVC e.g. polyolefin infusion bag with additive port cover. *Ideally infusion bag design will incorporate self sealing giving port to minimise H&S risks associated with accidental spillage during administration.*
	Starting materials	Licensed Etoposide 20mg/ml solution for injection Licensed Sodium Chloride 0.9% w/v Infusion bags
	Labelling	Labelling must be compliant with the principles of labelling for safety and the BP General specification on unlicensed medicines. There is no requirement for Tall Man lettering for the drug name.
	Label sample	An example label is provided below stating the minimum requirements only (the label format is not restrictive and suppliers can use their preferred layout):- Etoposide xxxmg in xxxml Sodium Chloride 0.9% w/v For Intravenous Infusion Infuse the entire contents of the bag Check the solution is free from particles before administering Store at Room Temperature Protect From Light Expiry: dd/mm/yyyy BN: XXXXXXXXX Keep out of the reach and sight of children Manufacturer's details MS XXXXXX .
	Batch Number	All products will have a unique batch identification number
	Latex status of - components - manufacturing process	All materials and manufacturing processes will be latex free or clearly labelled if not.
	Stability	Stability studies should conform to the Standard Protocol for deriving and assessment of stability of Aseptic preparations (small molecules) published by the NHS Pharmaceutical QA Committee (4th Edition, April 2017).